Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADVIL LIQUI-GELS vs ACULAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Mild to moderate pain,Primary dysmenorrhea,Osteoarthritis,Rheumatoid arthritis,Fever reduction,Migraine (off-label)
Treatment of postoperative inflammation in patients who have undergone cataract extraction,Relief of ocular itching due to seasonal allergic conjunctivitis
200–400 mg orally every 4–6 hours as needed; maximum 1200 mg/day.
One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.
1.8 to 2.5 hours. The short half-life supports dosing every 4 to 6 hours for acute pain and fever.
Terminal half-life: 1.8 hours (ketorolac tromethamine); clinical context: short half-life supports dosing every 6 hours for acute pain, but prolonged in elderly or renal impairment (↑ to 5-6 hours, thus dose reduction required).
Primarily hepatic via CYP2C9, with minor pathways including glucuronidation and CYP2C8. Metabolites are inactive.
Hepatic metabolism primarily via cytochrome P450 2C9 (CYP2C9).
Renal excretion of metabolites and conjugates accounts for approximately 90% of an administered dose. Less than 1% is excreted unchanged. Biliary/fecal elimination accounts for about 10%.
Renal: ~80% as unchanged drug and glucuronide conjugates; biliary/fecal: ~20%
Approximately 99% bound to albumin.
99% bound; primary binding protein: albumin.
0.1 to 0.2 L/kg. Low Vd reflects extensive protein binding and limited tissue distribution.
0.11-0.25 L/kg; clinical meaning: low Vd indicates primarily confined to extracellular compartment (plasma and interstitial fluid), minimal tissue penetration.
Oral bioavailability of ibuprofen from Liqui-Gels is approximately 85-90% due to first-pass metabolism.
Ophthalmic: ~2% systemic absorption after topical instillation (due to corneal permeability and nasolacrimal drainage); oral formulation not used for Acular (ophthalmic only).
e GFR 30–59 m L/min: maximum 800 mg/day in divided doses. e GFR <30 m L/min: contraindicated.
No dosage adjustment required for renal impairment.
Child-Pugh Class A: no adjustment. Class B: reduce dose by 50% and monitor. Class C: avoid use.
No dosage adjustment required for hepatic impairment.
Children ≥12 years: 200 mg orally every 4–6 hours, max 800 mg/day. Children <12 years: use weight-based ibuprofen (5–10 mg/kg/dose, max 40 mg/kg/day) not with Liqui-Gels formulation.
Safety and efficacy in pediatric patients have not been established; use not recommended.
Start at lowest effective dose; maximum 800 mg/day due to increased risk of GI and renal adverse effects.
No specific dosage adjustment required; use same dosing as for younger adults.
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
No FDA boxed warning.
Increased risk of gastrointestinal adverse events including bleeding, ulceration, and perforation; use lowest effective dose for shortest duration; avoid in patients with advanced renal disease; may cause hypertension or worsening of pre-existing hypertension; caution in patients with asthma, coagulation disorders, or fluid retention.
May increase bleeding time due to inhibition of platelet aggregation; use with caution in patients with known bleeding tendencies or those receiving other medications that may prolong bleeding time.,May cause corneal effects including keratitis and corneal thinning; discontinue if corneal epithelial breakdown occurs.,Use with caution in patients with prior sensitivity to aspirin, phenylacetic acid derivatives, or other NSAIDs.,May delay wound healing or exacerbate infections; avoid use in patients with active epithelial herpes simplex keratitis.
Hypersensitivity to ibuprofen or any component; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in CABG surgery; history of gastrointestinal bleeding or perforation related to NSAIDs; severe heart failure.
Hypersensitivity to ketorolac tromethamine or any component of the formulation,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Active epithelial herpes simplex keratitis,Late pregnancy (third trimester) due to risk of premature closure of ductus arteriosus
Alcohol increases risk of GI bleeding. No specific food restrictions; however, taking with high-fat meals may delay absorption but reduces GI irritation.
No known food interactions. Avoid alcohol if concomitant oral NSAIDs are used due to increased risk of gastrointestinal bleeding, but this is not specific to ophthalmic use.
First trimester: NSAIDs are associated with increased risk of miscarriage and cardiac defects. Second trimester: Generally considered safer; however, avoid prolonged use. Third trimester: Avoid due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal impairment.
Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairment in the third trimester. First and second trimester use should be avoided unless clearly needed. The potential benefits should be weighed against the risks.
Ibuprofen is excreted in breast milk in low concentrations (M/P ratio approximately 0.01). Considered compatible with breastfeeding by the AAP. Use lowest effective dose for shortest duration.
Ketorolac is excreted in human milk at low levels. The M/P ratio is not well defined. Due to potential adverse effects in nursing infants, caution is advised. Use only if clearly indicated and consider alternative agents.
No specific dose adjustment required based on pharmacokinetic changes. Use lowest effective dose for shortest duration. Avoid in third trimester.
No specific dose adjustments are recommended for pregnancy; however, use the lowest effective dose for the shortest duration due to potential fetal risks. Physiological changes in pregnancy (increased volume of distribution, renal clearance) may alter pharmacokinetics, but no formal studies justify dose modification.
Advil Liqui-Gels contain solubilized ibuprofen, allowing for faster absorption (onset ~20-30 min) compared to solid tablets. The liquid-filled gel capsule may cause more gastrointestinal distress in sensitive patients; administer with food. Avoid in patients with severe heart failure, history of GI bleed, or after coronary artery bypass grafting. Monitor renal function in elderly or dehydrated patients. Use lowest effective dose for shortest duration.
ACULAR (ketorolac tromethamine ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) used for ocular inflammation. Avoid concomitant use with other NSAIDs or corticosteroids due to increased risk of corneal adverse events. Use with caution in patients with bleeding disorders or those on anticoagulants, as it may increase bleeding tendency. Monitor for corneal toxicity, especially in patients with compromised corneal integrity. Ensure proper storage at room temperature and discard if solution changes color or becomes cloudy.
Take with food or milk to reduce stomach upset.,Do not exceed 1200 mg per day unless directed by a doctor.,Swallow whole; do not crush, chew, or break the capsule.,Avoid alcohol while taking this medication.,Stop and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (e.g., black/tarry stools).,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Do not take with other NSAIDs (e.g., aspirin, naproxen).
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not use while wearing soft contact lenses, as the preservative may be absorbed.,Report any signs of corneal problems such as pain, redness, or vision changes immediately.,Use exactly as prescribed and do not share the medication with others.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADVIL LIQUI-GELS vs ACULAR, answered by our medical review team.
ADVIL LIQUI-GELS is a NSAID that works by Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.. ACULAR is a NSAID Ophthalmic that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADVIL LIQUI-GELS and ACULAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADVIL LIQUI-GELS is: 200–400 mg orally every 4–6 hours as needed; maximum 1200 mg/day.. The standard adult dose of ACULAR is: One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADVIL LIQUI-GELS and ACULAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADVIL LIQUI-GELS is classified as Category C. First trimester: NSAIDs are associated with increased risk of miscarriage and cardiac defects. Second trimester: Generally considered safer; however, avoid prolonged use. Third tri. ACULAR is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairm. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.